Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial - PubMed
5 days ago
- #hypertension
- #clinical-trial
- #aldosterone
- Baxdrostat, a selective aldosterone synthase inhibitor, was tested in a phase 3 trial for resistant hypertension.
- The study was a randomized, double-blind, placebo-controlled trial involving 217 patients across 22 countries.
- Patients received either 2 mg baxdrostat or placebo once daily for 12 weeks, in addition to their background therapy.
- The primary endpoint was the change in 24-hour ambulatory systolic blood pressure (SBP) from baseline to week 12.
- Baxdrostat significantly reduced 24-hour ambulatory SBP by -14.0 mm Hg compared to placebo (p<0.0001).
- Adverse events occurred in 52% of baxdrostat recipients versus 37% in the placebo group.
- Three patients in the baxdrostat group had confirmed potassium levels >6 mmol/L, a potential safety concern.
- The study supports aldosterone synthase inhibition as a promising treatment for resistant hypertension.
- Funding and conflicts of interest were disclosed, with several authors having ties to AstraZeneca and other pharmaceutical companies.